A man in his 40s of Middle Eastern descent, with no prior medical history, presented with severe abdominal pain that had ...

Rilparencel, a percutaneous minimally invasive injectable product prepared from patients’ own kidney cells, is being developed to treat those with stage 3b or 4 CKD and either type 1 or type 2 ...

Povetacicept is an investigational dual BAFF and APRIL inhibitor being tested for various glomerulonephritis types in clinical trials.

Experts say we’re in a golden age for treating chronic kidney disease, with new drugs like Ozempic yielding major results.

These studies represent promising new treatment options for chronic and progressive kidney diseases, offering renewed hope to ...

In this video, Anjay Rastogi, MD, PhD, professor and Clinical Chief of Nephrology at the David Geffen School of Medicine at UCLA, discusses the screening process for chronic kidney disease.

ACEI and ARB use in CKD has been available for over three decades, but it is still underutilized. Now, a new clinical ...

Background: Among patients with focal segmental glomerulosclerosis (FSGS), proteinuria and kidney function decline may be ...

Stories describing what can happen when science is manipulated or misapplied are among the winners of the 2025 AAAS Kavli Science Journalism Awards. Winning journalists also did stories on science at ...

The United Nations’ international food standards-setting body, the Codex Alimentarius Commission, has set the maximum ...

SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or ...

Chronic kidney disease (CKD) represents a global health issue with a high socioeconomic impact. Beyond a progressive decline of kidney function, patients with CKD are at increased risk of ...